SCHEMBL5107465

SCHEMBL5107465

CCOc1nc(NCc2ccc(F)cc2)nc2ccc(-c3ccc(C(=O)NC4CC4)cc3)nc12

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 8/20 0.47
TCF7L2 Q9NQB0 8/20 0.47
MAPT P10636 1/20 0.42
TSHR P16473 1/20 0.42
HPGD P15428 1/20 0.41
NAMPT P43490 1/20 0.41
ADRA2A P08913 2/20 0.40
MCHR1 Q99705 2/20 0.40
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
SSTR5 P35346 4/20 0.40
SSTR3 P32745 1/20 0.40
GABRA5 P31644 1/20 0.40
ADRA1A P35348 1/20 0.40
HRH1 P35367 1/20 0.40
HTR2B P41595 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5116771 0.89 NAMPT (0.39) CTNNB1TCF7L2HPGDNAMPTADRA2A
SCHEMBL5122180 0.89 CA1 (0.46) MAPTTSHRHPGDMKNK1MKNK2
SCHEMBL5114918 0.88 RECQL (0.42) CTNNB1TCF7L2
SCHEMBL5114661 0.86 VNN1 (0.39) CTNNB1TCF7L2MAPTADRA2A
SCHEMBL5117245 0.86 VNN1 (0.39) CTNNB1TCF7L2MAPTADRA2A
SCHEMBL3334259 0.85 CTNNB1 (0.53) CTNNB1TCF7L2MAPTTSHRADRA2A
SCHEMBL5123850 0.85 MAPT (0.43) MAPTHPGDMKNK1
SCHEMBL5123118 0.85 MAP4K4 (0.47) CTNNB1TCF7L2MAPTNAMPTMCHR1
SCHEMBL5115390 0.84 CYP1A2 (0.42) CTNNB1TCF7L2MAPTTSHRHPGD
SCHEMBL5121915 0.84 MAP4K4 (0.46) CTNNB1TCF7L2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8729089-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-05-20 US disclosed
US-8729089-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-05-20 US disclosed
US-8729089-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-05-20 US disclosed
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-31 US disclosed
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-31 US disclosed
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-31 US disclosed
WO-2008077651-A1 PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS PNPO, DPYD, PNP CTNNB1 1384/4885TCF7L2 3616/4885MAPT 3290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.